Hypothesis: Platelet-Rich Plasma as an Adjunct Therapy for Eczema Targeting Inflammation, Skin Barrier Repair, and Chronic Recurrence

The document hypothesizes that platelet-rich plasma (PRP) could be an effective adjunct therapy for eczema by addressing inflammation, repairing the skin barrier, and reducing chronic recurrence. Eczema involves immune dysregulation and barrier dysfunction, and current treatments often have side effects or limited efficacy. PRP, which contains growth factors and bioactive molecules, has shown promise in treating conditions like alopecia areata and psoriasis, which share similarities with eczema. Despite the lack of systematic studies on PRP for eczema, its safety profile and potential to modulate immune responses and enhance barrier function suggest it could be beneficial, warranting further clinical trials.